IL42314A - Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis - Google Patents

Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis

Info

Publication number
IL42314A
IL42314A IL42314A IL4231473A IL42314A IL 42314 A IL42314 A IL 42314A IL 42314 A IL42314 A IL 42314A IL 4231473 A IL4231473 A IL 4231473A IL 42314 A IL42314 A IL 42314A
Authority
IL
Israel
Prior art keywords
antacid
pharmaceutical composition
acid
composition according
glycyrrhetinic acid
Prior art date
Application number
IL42314A
Other versions
IL42314A0 (en
Original Assignee
Biorex Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Laboratories Ltd filed Critical Biorex Laboratories Ltd
Publication of IL42314A0 publication Critical patent/IL42314A0/en
Publication of IL42314A publication Critical patent/IL42314A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1401360 Pharmaceutical compositions BIOREX LABORATORIES LTD 29 Nov 1973 [18 Dec 1972] 58355/72 Heading A5B Pharmaceutical compositions for use in the treatment of gastritis in dosage unit form comprise 1-100 mg of at least one non-ulcerogenic, anti-inflammatory active derivative of glycyrrhetinic acid (selected from the esters, hemiesters and hemiester salts thereof e.g. the disodium salt of glycyrrhetininc acid hemisuccinate, the salts of glycyrrhetinic acid with non-toxic organic bases; the salts of glycyrrhetinic acid and its hemiesters with bismuth, zinc or a metal of Group IIA, IIIA or VIII of the Periodic Table; and the amides of glycyrrhetininc acid and of acylated glycyrrhetininc acid), in admixture with 1-70% by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound (such as aluminium hydroxide, aluminium magnesium silicate, aluminium phosphate, or dihydroxyaluminium aminoacetate). The antacid aluminium compound may be partially replaced by other known antacid compounds e.g. calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate or sodium bicarbonate. The composition may be administered orally in the form of a tablet. [GB1401360A]

Claims (2)

What we claim is:- 1. A pharmaceutical composition in dosage unit form for the treatment of gastritis comprising 1-100 mg of at least one non-ulcerogenic, anti-inflammatory active derivative of glycyrrhetinic acid (as hereinbefore defined) in admixture with
1. -70$ by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound(as hereinbefore defined). 2. A pharmaceutical composition according to claim 1 wherein said dosage unit has a weight of 0.10-3.0 g. 5. A pharmaceutical composition according to claim 2, wherein said dosage unit has a weight of 0.
2. -2.0 g. 4. pharmaceutical composition according to any of the preceding claims, an wherein the glycyrrhetinic acid derivative is present in amount of from 10-50 mg. 5. A pharmaceutical composition according to any of the preceding claims, wherein the antacid is present in an amount of from 15-60 by veight. 6. A pharmaceutical composition according to any of the preceding claims, wherein the antacid aluminium compound is partially replaced by other known antacid compounds. 7. pharmaceutical composition according to any of the preceding claims, wherein the glycyrrhetinic acid derivative ίε the dlsodium salt of glycyrrhetinic acid hemisuccinate. 8. A pharmaceutical composition according to any of the preceding claims, which additionally comprises at least one pharmaceutical diluent or carrier and/or at least one flavouring agent and/or at least one sweetening agent and/or at least one colouring material. 9. A pharmaceutical composition according to claim , substantially as hereinbefore described and exemplified*
IL42314A 1972-12-18 1973-05-20 Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis IL42314A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5835572A GB1401360A (en) 1972-12-18 1972-12-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
IL42314A0 IL42314A0 (en) 1973-07-30
IL42314A true IL42314A (en) 1976-09-30

Family

ID=10481403

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42314A IL42314A (en) 1972-12-18 1973-05-20 Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis

Country Status (10)

Country Link
AU (1) AU476390B2 (en)
BE (1) BE802701A (en)
CA (1) CA1018457A (en)
DE (1) DE2360889A1 (en)
FR (1) FR2210400B1 (en)
GB (1) GB1401360A (en)
IE (1) IE38521B1 (en)
IL (1) IL42314A (en)
NL (1) NL7317237A (en)
ZA (1) ZA732439B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8307096A1 (en) * 1981-06-01 1983-07-01 Orion Yhtymae Oy Tablets which do not damage the oesophagus.
GB2122893B (en) * 1982-06-30 1985-06-26 Biorex Laboratories Ltd Glycyrrhetinic acid compositions
AU553789B2 (en) * 1982-06-30 1986-07-24 Biorex Laboratories Ltd. Glycyrrhetinic acid derivatives in cream compositions
US4861591A (en) * 1987-11-18 1989-08-29 American Home Products Corporation Formulations for hygroscopic pharmaceuticals

Also Published As

Publication number Publication date
NL7317237A (en) 1974-06-20
FR2210400A1 (en) 1974-07-12
BE802701A (en) 1974-01-23
AU6312773A (en) 1975-06-05
IE38521B1 (en) 1978-03-29
IE38521L (en) 1974-06-18
DE2360889A1 (en) 1974-06-20
ZA732439B (en) 1974-03-27
FR2210400B1 (en) 1977-07-15
IL42314A0 (en) 1973-07-30
GB1401360A (en) 1975-07-16
CA1018457A (en) 1977-10-04
AU476390B2 (en) 1976-09-16

Similar Documents

Publication Publication Date Title
US3773946A (en) Triglyceride-lowering compositions and methods
IE38520B1 (en) Pharmaceutical composition
ES8107231A1 (en) Cephem and cepham compounds, processes for their preparation, pharmaceutical compositions containing them.
SE7614258L (en) PROCEDURE FOR THE PREPARATION OF CHINAZOLO DERIVATIVE
ES475338A1 (en) o-Substituted (+)-cyanidan-3-ol derivatives, method for their preparation, as well as pharmaceutical compositions containing these compounds and their preparation.
IL42314A (en) Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis
US3845097A (en) N-substituted amino acids and novel ester
EP0028336B1 (en) Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions
IL65787A0 (en) Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines
US3787581A (en) Pharmaceutical compositions and methods of treatment
US3501577A (en) Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate
GB906331A (en) Appetite-reducing compositions comprising phenylamino propane derivatives
EP0340540B1 (en) Agent for the prophylaxis of a heart infarct and for the prevention of another infarct
ES469804A1 (en) 6-Azaoligocycloalkylmethyleneaminopenam compounds
ES8305759A1 (en) Pyrrolidinone derivatives, their preparation and pharmaceutical compositions containing them.
US3766168A (en) N6-(chlorobuten - 2 - yl)-adenosines and processes for the preparation thereof
US3644448A (en) Crystalline hydrates of alkali metal salts of zinc trans-1 2-diaminocyclohexane-n n n' n'-tetraacetate
US3887706A (en) N6-(3-Chlorobuten-2-yl)-adenosines as anti-inflammatory agents
GB1276589A (en) 0-alkyl-6-azauracil compounds and compositions containing the same
GB1350929A (en) Pharmaceutical compositions
US2598004A (en) Stabilized tetrathiodilactic and tetathiodiglycollic acid pharmaceutical
GB1464082A (en) Pharmaceutical 'ompositions containing benzylamines
US3501576A (en) Method of treating hypertension with alkali metal salts of zinc trans - 1,2 - diaminocyclohexane-n,n,n',n'-tetraacetate
GB1217822A (en) Pharmaceutical compositions
US4093719A (en) Antiarthritic compositions comprising bis[(trialkyl-phosphine)gold(I)]sulfides and methods of producing antiarthritic activity